The public should be able to identify which products have been authorised for parallel importation, who is responsible for them and how compliance will be monitored.
By
John M. Mwangi
Pharmaceutical Industry Expert
The Ministry of Health’s decision to halt unregulated parallel importation of medicines and health technologies marks an important step in strengthening Kenya’s pharmaceutical regulatory system.
More than a policy shift, it is a reaffirmation that improving access to medicines should never come at the expense of patient safety, quality or public confidence.
The economics behind Kenya’s pharmaceutical industry are shaping which medicines reach patients.
Despite constraints, Kenya remains the most advanced pharmaceutical manufacturer in East Africa and the third-largest exporter of…
Health Ministry proposes amendments to enhance drug import efficiency, facilitating research by simplifying regulations and…
This fall could be attributed to several factors, including declining global input costs for pharmaceutical raw materials and…
Kenya's heavy reliance on imported medicines contributes to high drug prices and limits access to affordable healthcare.
Kenya's heavy reliance on imported medicines contributes to high drug prices and limits access to affordable healthcare.
